BIBiocon532523Earnings call transcript

Q2 FY27 call: Pebrilzo launch dates secured, over $100 million new North America contracts

Transcript of Biocon's Q2 FY27 earnings call held on November 04, 2026.

By ScoutQuest · Wed 11 Nov 2026, 11:17 PM IST · 2 min read

Pebrilzo licensed launch dates

EU and U.K. from early calendar 2027, U.S. from Q3 calendar 2028, subject to regulatory approvals

New contracts in North America

Over $100 million in new contracts and major payor wins

Malaysia insulin capacity

Second fill-finish line commissioned in Malaysia for insulin capacity

Management's opening remarks on the Q2 FY27 earnings call, held on November 04, 2026, centred on three things: moving from investment to commercial scale, the Genentech settlement for Pebrilzo, and an outlook for a stronger second half.

Key outcomes from the call

• A global settlement and license agreement with Genentech for Pebrilzo, the biosimilar Pertuzumab. Management said this secures the earliest licensed launch dates for the product, subject to regulatory approvals.
• A positive CHMP opinion was received during the quarter for the same product.
• A second fill-finish line was commissioned in Malaysia, expanding insulin manufacturing capacity.
• In North America, over $100 million in new contracts and major payor wins covering a majority of the U.S. population were added during the quarter.
• FDA approval was received for the Yesintek single-dose prefilled autoinjector, strengthening the immunology offering in the U.S. and Canada.

Launch timeline mentioned

• EU and U.K.: from early calendar 2027.
• U.S.: from Q3 calendar 2028.

Guidance and outlook

• Management said the first half of FY27 reinforced its outlook for a previously stated stronger second half, which it is very confident to deliver on.
• The company described itself as moving decisively from investment-led capability building to commercial acceleration, operating leverage and value creation.
• Syngene's CDMO platform was described as a second engine of growth alongside biosimilars.

Market commentary

• North America remains the largest and most strategically important market, with Insulin Glargine, Ogivri and Fulphila maintaining leadership positions in their respective segments.
• Yesintek, the biosimilar Ustekinumab, showed encouraging momentum, and Yesafili, the biosimilar Aflibercept, is following its U.S. launch, with management pleased with the initial response.
• Europe continues to be built through portfolio expansion, market access and a combination of retail and tender-based commercial strategies.

What a retail reader can take away

• The Genentech settlement gives dated market entry points for a key biosimilar in the EU, U.K. and U.S., which lets an investor place the launch on a timeline rather than treat it as open-ended.
• The over $100 million of new contracts is a commercial order-flow indicator for the North American business.
• The additional insulin fill-finish line in Malaysia is a supply-side expansion that management links to future volumes.
• The stronger second half is management's stated expectation on a call that carries a safe harbour note, so it is an outlook rather than a reported result.
• All launch dates are described as subject to regulatory approvals.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev